Close

Forgot your password?

Choose a newsletter




Premium access provided by ENSTA

Your premium access provided by ENSTA

Enter your email to begin

Premium access granted to you by NRC Q

You have been given free premium access to Worldcrunch for 8 weeks thanks to NRC Q.

Enter your email to begin

Premium access granted to you by EM-LYON

You have been given free premium access to Worldcrunch for 8 weeks thanks to EM-LYON.

Enter your email to begin

Premium access granted to you by Goldsmiths

You have been given free premium access to Worldcrunch for 8 weeks thanks to Goldsmiths.

Enter your email to begin

Premium access granted to you by Worldcrunch HQ

You have been given free premium access to Worldcrunch for 8 weeks thanks to Worldcrunch HQ.

Enter your email to begin

Premium access granted to you by MINES Alès Alumni

You have been given free premium access to Worldcrunch for 8 weeks thanks to MINES Alès Alumni.

Enter your email to begin

Premium access granted to you by ESCP Europe Alumni

You have been given free premium access to Worldcrunch for 8 weeks thanks to ESCP Europe Alumni.

Enter your email to begin

Premium access granted to you by IONIS Education Group

You have been given free premium access to Worldcrunch for 8 weeks thanks to IONIS Education Group.

Enter your email to begin

Premium access granted to you by SOAS University of London

You have been given free premium access to Worldcrunch for 8 weeks thanks to SOAS University of London.

Enter your email to begin

Premium access granted to you by Contact Expats

You have been given free premium access to Worldcrunch for 8 weeks thanks to Contact Expats.

Enter your email to begin

Premium access granted to you by Financial Review Beyond

You have been given free premium access to Worldcrunch for 8 weeks thanks to Financial Review Beyond.

Enter your email to begin

Premium access granted to you by MinnPost

You have been given free premium access to Worldcrunch for 6 months thanks to MinnPost.

Enter your email to begin

Premium access granted to you by Expatica

You've been given FREE premium access to Worldcrunch

Enter your email to begin

Worldcrunch

Death Penalty: Europe Restricts Export Of Drug Used In American Lethal Injections

Exclusive: Pushed by human rights groups, the European Union is set to ban the sale to the United States of one of the main active substances needed for lethal injections. Sodium thiopental is already in short supply, and executions are now set to be further delayed.

Article illustrative image Partner logo Lethal injection room in California's San Quentin State Prison

BERLIN - The European Union is set to restrict the sale to the United States of one of the main active substances needed for lethal injections. According to information obtained by the Süddeutsche Zeitung, the export of sodium thiopental will only be possible by special permission, beginning Friday, posing a major problem for the US justice system.

The Official Journal of the European Union (OJ) is to publish a new, uniform set of authorized export regulations, valid for all short or intermediate-acting barbituric acids. One of them is the easy-to-use and fast-working anesthetic sodium thiopental, which is used to execute criminals in the states of Ohio and Washington. In 33 other states, sodium thiopental is a key ingredient in other toxic cocktails used to kill inmates.

Approximately 100 people are executed by American authorities every year. But in the past few months, supplies of the drug have become scarce. The only manufacturer based in the US, Hospira, is unwilling to continue to make its product available for lethal injections, and under American law it is not allowed to simply change the injection “recipe.” To do that, a complicated approval procedure is required. So authorities -- who have been postponing executions as a result of the difficulty in finding supplies -- have been seeking other sources such as those in the EU.

Anti-death penalty and other human rights groups have pushed for the EU decision to now require special permission to export to countries outside of Europe. The most prominent supporter of the move is Germany’s Minister of Economy and head of the Free Democratic Party (FDP), Philipp Rösler. In an earlier role as Minister of Health he had written to German manufacturers of sodium thiopental to encourage them not to sell the drug to the US.

After changing jobs, he introduced to the Commission a bill to create a regulation valid Europe-wide that would effectively prevent the export of thiopental to the US. Initially, the proposal met with resistance from other states, but it has now been approved by the majority of the 27 member states.

Read the original article in German

Photo - Wikipedia

 

Sign up for our Worldcrunch Weekly newsletter now


Be a part of the conversation. Click to show comments
About this article source Website: http://www.sueddeutsche.de/

Suddeutsche Zeitung is one of Germany's premiere daily quality newspapers. It was founded on 6 October 1945, and has been called "The New York Times of Munich".

Load More Stories

Unlimited access to exclusive journalism, the best world news source across all your devices

Subscribe Now Photo of Worldcrunch on different devices

Your premium access to Worldcrunch is provided by

University of Central Lancashire

Please register to begin


By registering you agree to our terms of service and privacy policy.